Sunshine Biopharma is trading at $2.88, up 8.68% in pre-market on November 5, 2026, with no definitive catalyst identified.
- No new company-specific announcement was identified; its press-release page lists the October 22 reverse-split announcement as its latest release.
- Biotechnology-sector strength may be supporting the move: the sector ETF was up 2.08% pre-market, with broader biotech sentiment buoyed by Amgen’s recent earnings and outlook.